IPSEN, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy

Completed

Conditions: Prostate Cancer

Interventions: Other: Data collection

First Posted Date: 2018-05-04

Last Posted Date: 2020-04-30

Lead Sponsor: Ipsen

Target Recruit Count: 831

Registration Number: NCT03516110

Locations: 🇫🇷
Ipsen Central Contact, Paris, France

Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Telotristat etiprate

First Posted Date: 2018-02-22

Last Posted Date: 2020-04-08

Lead Sponsor: Ipsen

Target Recruit Count: 16

Registration Number: NCT03442725

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇲🇩
ARENSIA Exploratory Medicine Phase I Unit, Republican Clinical Hospital, Chisinau, Moldova, Republic of
🇧🇪
A.T.C. s.a., Clinical Pharmacology Unit, CHU Sart-Tilman, Liège, Belgium

and more 1 locations

Validation of the Spasticity Related Quality of Life Questionnaire

Not Applicable

Completed

Conditions: Spasticity, Muscle

Interventions: Other: Data collection

First Posted Date: 2018-02-22

Last Posted Date: 2019-09-30

Lead Sponsor: Ipsen

Target Recruit Count: 104

Registration Number: NCT03442660

Locations: 🇬🇧
Mid Yorkshire Hospitals NHS Trust, Dewsbury Hospital, Dewsbury, United Kingdom
🇬🇧
City Hospitals Sunderland NHS Foundation Trust Research and Innovation Education Centre, Sunderland, United Kingdom
🇬🇧
Hull and East Yorkshire NHS Trust, Castle Hill Hospital, Cottingham, United Kingdom

and more 5 locations

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

Completed

Conditions: Renal Cell Carcinoma

Interventions: Other: Data collection

First Posted Date: 2018-02-05

Last Posted Date: 2022-08-15

Lead Sponsor: Ipsen

Target Recruit Count: 689

Registration Number: NCT03419572

Locations: 🇦🇹
Kepler University Hospital - Urology, Linz, Austria
🇦🇹
Universitatsklinikum fur Urologie und Andrologie, Salzburg, Austria
🇧🇪
Imelda Ziekenhuis, Bonheiden, Belgium

and more 88 locations

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Phase 3

Completed

Conditions: Endometriosis

Interventions: Drug: Triptorelin Acetate PR 1-month
Drug: Triptorelin Pamoate PR 3-month

First Posted Date: 2017-07-27

Last Posted Date: 2021-10-14

Lead Sponsor: Ipsen

Target Recruit Count: 300

Registration Number: NCT03232281

Locations: 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳
Chinese PLA General Hospital, Beijing, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

and more 21 locations

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Phase 2

Completed

Conditions: Gastro-Enteropancreatic Neuroendocrine Tumor

Interventions: Drug: Satoreotide trizoxetan 5-20μg
Drug: Satoreotide trizoxetan 30-45μg

First Posted Date: 2017-07-18

Last Posted Date: 2021-01-14

Lead Sponsor: Ipsen

Target Recruit Count: 29

Registration Number: NCT03220217

Locations: 🇦🇹
Medical University of Innsbruck, Innsbruck, Austria
🇦🇹
University Clinic for Radiology and Nuclear Medicine, Vienna, Austria
🇺🇸
UCLA Medical Center, Los Angeles, California, United States

and more 2 locations

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain

Completed

Conditions: Neuroendocrine Tumors

Interventions: Other: Data collection

First Posted Date: 2017-07-18

Last Posted Date: 2018-12-21

Lead Sponsor: Ipsen

Target Recruit Count: 142

Registration Number: NCT03220087

Locations: 🇪🇸
Hospital General Univ. de Elche, Alicante, Spain
🇪🇸
ICO Badalona, Badalona, Spain
🇪🇸
Hospital Clínico y Provincial de Barcelona, Barcelona, Spain

and more 25 locations

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Completed

Conditions: Neuroendocrine Tumors

First Posted Date: 2017-04-13

Last Posted Date: 2020-06-02

Lead Sponsor: Ipsen

Target Recruit Count: 93

Registration Number: NCT03112694

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

and more 5 locations

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Irinotecan liposome injection
Drug: Topotecan

First Posted Date: 2017-03-23

Last Posted Date: 2024-07-17

Lead Sponsor: Ipsen

Target Recruit Count: 491

Registration Number: NCT03088813

Locations: 🇺🇸
Florida Cancer Specialists (South Region), Fort Myers, Florida, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States

and more 115 locations

Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea

Phase 1

Completed

Conditions: Chronic Functional Diarrhea of Unknown Origin

Interventions: Drug: Diosmectite (Smecta®)

First Posted Date: 2017-02-08

Last Posted Date: 2019-04-05

Lead Sponsor: Ipsen

Target Recruit Count: 35

Registration Number: NCT03045926

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands
🇬🇧
MAC Clinical Research Limited, Manchester, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy